Xiaonan ZHANG

Xiaonan ZHANG is an Associate Professor in the Faculty of Science and Technology at the University of Canberra, leading the Hepatitis B Virus (HBV) Group within the Centre for Research into Therapeutic Solutions. He holds a PhD from Fudan University (2012) and previously worked at the Shanghai Public Health Clinical Centre until 2021. His research focuses on HBV molecular pathogenesis, therapeutic vaccine development, and next-generation sequencing applications in viral infections.

His work has advanced understanding of HBV’s clinical outcomes, including the discovery of Capsid-Antibody-Complexes (CACs) and their role in pathogenesis. Collaborations span institutions like the Peter Doherty Institute, University of Queensland, and international partners such as Fudan University and University of Duisburg-Essen. Key projects include:

• Development of therapeutic mRNA vaccines for chronic HBV
• Clinical evaluation of CAC assays in HBV/HIV co-infections
• Metagenomic sequencing for pathogen identification

Research interests emphasize translational medicine, with contributions to H7N9 influenza and SARS-CoV-2 studies during the pandemic. His team pioneered real-world analyses of viral and host factors in COVID-19 outcomes. Current focus includes liver-resident immune cell dynamics and novel diagnostic assays for HBV nucleic acids.

Publications highlight innovations in HBV cccDNA tracking, immune complex mechanisms, and exosome-mediated signaling. No scientific awards were explicitly listed in the provided texts.

Xiaonan actively collaborates on grants and supervises PhD students, advancing interdisciplinary approaches to viral diseases.